United States - English - NLM (National Library of Medicine)

mylan institutional llc - ascorbic acid (unii: pq6ck8pd0r) (ascorbic acid - unii:pq6ck8pd0r) - ascorbic acid is recommended for the prevention and treatment of scurvy. its parenteral administration is desirable for patients with an acute deficiency or for those whose absorption of orally ingested ascorbic acid is uncertain. symptoms of mild deficiency may include faulty bone and tooth development, gingivitis, bleeding gums, and loosened teeth. febril states, chronic illness, and infection (pneumonia, whooping cough, tuberculosis, diphtheria, sinusitis, rheumatic fever, etc.) increases the need for ascorbic acid. hemovascular disorders, burns, delayed fracture and wound healing are indications for an increase in the daily intake. there are no contraindications to the administration of ascorbic acid.

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

sykes vet (international) pty. ltd. - calcium as calcium carbonate, di-calcium phosphate and c; cobalt as cobalt (ii) sulfate; copper (cu) present as copper sulfate; iron as ferrous sulfate; magnesium as magnesium sulfate; manganese as manganese (ii) sulfate; zinc as zinc oxide; vitamin a; vitamin c = ascorbic acid; vitamin d3; vitamin e; vitamin k3 - oral powder, pre-mix - calcium as calcium carbonate, di-calcium phosphate and c mineral-calcium active 333.3 g/kg; cobalt as cobalt (ii) sulfate mineral-cobalt active 1.1 g/kg; copper (cu) present as copper sulfate mineral-copper active 1.2 g/kg; iron as ferrous sulfate mineral-iron active 3.7 g/kg; magnesium as magnesium sulfate mineral-magnesium active 17.6 g/kg; manganese as manganese (ii) sulfate mineral-manganese active 7.3 g/kg; zinc as zinc oxide mineral-zinc active 3.2 g/kg; vitamin a vitamin-a active 900000.0 iu/kg; vitamin c = ascorbic acid vitamin-c active 5390.0 mg/kg; vitamin d3 vitamin-d3 active 1200.0 mg/kg; vitamin e vitamin-e active 2600.0 iu/kg; vitamin k3 vitamin-k3 active 750.0 mg/kg - nutrition & metabolism - horse | colt | donkey | endurance horse | filly | foal | gelding | high performance horses | horses at stud | mare | pacer | pol - calcium supplement | iron deficiency | phosphorus deficiency | vitamin & mineral deficiency | anaemia

United States - English - NLM (National Library of Medicine)

ferring pharmaceuticals inc. - sodium picosulfate (unii: lr57574hn8) (deacetylbisacodyl - unii:r09078e41y), magnesium oxide (unii: 3a3u0gi71g) (magnesium cation - unii:t6v3lhy838), anhydrous citric acid (unii: xf417d3psl) (anhydrous citric acid - unii:xf417d3psl) - sodium picosulfate 10 mg in 16.1 g - prepopik® is indicated for cleansing of the colon as a preparation for colonoscopy in adults and pediatric patients 9 years of age and older. prepopik is contraindicated in the following conditions: - patients with severe renal impairment (creatinine clearance less than 30 ml/minute) which may result in accumulation of magnesium [see warnings and precautions (5.4)] - gastrointestinal obstruction or ileus [see warnings and precautions (5.6)] - bowel perforation [see warnings and precautions (5.6)] - toxic colitis or toxic megacolon - gastric retention - hypersensitivity to any of the ingredients in prepopik [see adverse reactions (6.2)] risk summary there are no data with prepopik use in pregnant women to determine a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. in an animal reproduction study, no adverse developmental effects were observed in pregnant rats when sodium picosulfate, magnesium oxide, and anhydrous citric acid were administered orally at doses 1

United States - English - NLM (National Library of Medicine)

deseret biologicals, inc. - ascorbic acid (unii: pq6ck8pd0r) (ascorbic acid - unii:pq6ck8pd0r) - ascorbic acid 6 [hp_x] in 1 ml - for temporary relief of symptoms of vitamin c deficiency such as lack of energy, weakness, swollen and tender joints. for temporary relief of symptoms of vitamin c deficiency such as lack of energy, weakness, swollen and tender joints.

United States - English - NLM (National Library of Medicine)

mcguff pharmaceuticals, inc. - ascorbic acid (unii: pq6ck8pd0r) (ascorbic acid - unii:pq6ck8pd0r) - ascorbic acid 500 mg in 1 ml - ascor is vitamin c indicated for the short term (up to 1 week) treatment of scurvy in adult and pediatric patients age 5 months and older for whom oral administration is not possible, insufficient or contraindicated. limitations of use ascor is not indicated for treatment of vitamin c deficiency that is not associated with signs and symptoms of scurvy. none. use in specific populations 8.1 pregnancy 8.2 lactation 8.4 pediatric use 8.5 geriatric use 8.6 renal impairment 8.1 pregnancy risk summary there are no available data on use of ascor in pregnant women to inform a drug-associated risk of adverse developmental outcomes; however, use of ascorbic acid (vitamin c) has been used during pregnancy for several decades and no adverse developmental outcomes are reported in the published literature [see data]. there are dose adjustments for ascorbic acid (vitamin c) use during pregnancy [ see clinical considerations ]. animal reproduction studies have not been conducted with ascor. the estimated background risk of major birth defects and miscarriage for the indicated population is unknown. all pregnancies have a background risk of birth defect, loss, or other adverse outcomes. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively. clinical considerations dose adjustments during pregnancy and post-partum period follow the u.s. recommended dietary allowances (rda) for pregnant women when considering use of ascor for treatment of scurvy [ see dosage and administration (2.3 )]. data human data there are no available data on use of ascor or another ascorbic acid injection in pregnant women. however, a published meta–analysis of randomized studies evaluating a large number of pregnant women who took oral ascorbic acid (vitamin c) (through diet and supplementation) at doses ranging from 500 to1000 mg/day (2.5 to 5 times the recommended daily intravenous dose, respectively) [ see dosage and administration (2.3) ] between the 9th and 16th weeks of pregnancy showed no increased risk of adverse pregnancy outcomes such as miscarriage, preterm premature rupture of membranes, preterm delivery or pregnancy induced hypertension when compared to placebo. these data cannot definitely establish or exclude the absence of a risk with ascorbic acid (vitamin c) during pregnancy. 8.2 lactation risk summary there are no data on the presence of ascorbic acid (vitamin c) in human milk following intravenous dosing in lactating women. ascorbic acid (vitamin c) is present in human milk after maternal oral intake. maternal oral intake of ascorbic acid (vitamin c) exceeding the u.s. recommended dietary allowances (rda) for lactation does not influence the ascorbic acid (vitamin c) content in breast milk or the estimated daily amount received by breastfed infants. there are no data on the effect of ascorbic acid (vitamin c) on milk production or the breastfed infant. the developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for ascor and any potential adverse effects on the breastfed child from ascor or from the underlying maternal condition. follow the u.s. recommended dietary allowances (rda) for lactating women when considering use of ascor for treatment of scurvy [see dosage and administration (2.3) ]. 8.4 pediatric use ascor is indicated for the short term (up to 1 week) treatment of scurvy in pediatric patients age 5 months and older for whom oral administration is not possible, insufficient or contraindicated. the safety profile of ascorbic acid in pediatric patients is similar to adults; however, pediatric patients less than 2 years of age may be at higher risk of oxalate nephropathy following ascorbic acid administration due to age-related decreased glomerular filtration [ see warnings and precautions (5.1 )]. ascor is not indicated for use in pediatric patients less than 5 months of age. 8.5 geriatric use glomerular filtration rate is known to decrease with age and as such may increase risk for oxalate nephropathy following ascorbic acid administration in elderly population [ see warnings and precautions (5.1 ) ]. 8.6 renal impairment ascor should be used with caution in scorbutic patients with a history of or risk of developing renal oxalate stones or evidence of renal impairment or other issues (e.g., patients on dialysis, patients with diabetic nephropathy, and renal transplant recipients). these patients may be at increased risk of developing acute or chronic oxalate nephropathy following high dose ascorbic acid administration [ see warning and precaution (5.1 ].

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

kent pharma (uk) ltd - ascorbic acid - oral tablet - 100mg

United States - English - NLM (National Library of Medicine)

guna spa - ascorbic acid (unii: pq6ck8pd0r) (ascorbic acid - unii:pq6ck8pd0r), sus scrofa conjunctiva (unii: w61me6q717) (sus scrofa conjunctiva - unii:w61me6q717), prasterone (unii: 459ag36t1b) (prasterone - unii:459ag36t1b), malic acid (unii: 817l1n4ckp) (malic acid - unii:817l1n4ckp), fucus vesiculosus (unii: 535g2abx9m) (fucus vesiculosus - unii:535g2abx9m), histidine monohydrochloride (unii: 1d5q932xm6) (histidine - unii:4qd397987e), hyaluronidase (unii: 8kog53z5em) (hyaluronidase - unii:8kog53z5em), human - ascorbic acid 4 [hp_x] in 30 ml - ascorbic acid 4x antioxidant conjunctiva tissue 6x detoxification dehydroepiandrosteron 6x hormonal support dl-malic acid 6x promote cell metabolism fucus vesiculosus 4x detoxification histidine 4x anti-inflammatory hyaluronidase 6x anti-inflammatory interleukin 6 4c immune support lacticum acidum 4x antioxidant lymphatic vessel 6x immune support nadidum 6x metabolic support natrum oxalaceticum 6x antioxidant natrum pyruvicum 6x antioxidant natrum sulphuricum 6x, 8x, 12x, 30x, 200x antioxidant phenylalanine 4x improve concentration prolactin 6x improve concentration

United States - English - NLM (National Library of Medicine)

international isotopes inc - sodium iodide i-131 (unii: 29vco8achh) (iodide ion i-131 - unii:4gc1foq22u) - sodium iodide i-131 solution is indicated for the treatment of hyperthyroidism and selected cases of thyroid carcinoma. sodium iodide i-131 is contraindicated in: - patients with vomiting and diarrhea [see warning and precautions (5.7)] . - patients with thyroid malignancies shown to have no iodide uptake, which include the majority of medullary or anaplastic carcinomas. - patients receiving concurrent anti-thyroid therapy [see warning and precautions (5.1) and drug interactions (7)] . - pregnancy [see warnings and precautions (5.4), see use in specific populations (8.1)] . - lactation [see warnings and precautions (5.5)] . risk summary sodium iodide i-131 is contraindicated in pregnancy because fetal exposure can lead to neonatal hypothyroidism, which in some cases is severe and irreversible [see warnings and precautions (5.4)] . data from the published literature describe thyroid abnormalities after fetal exposure; including agenesis of the thyroid and hypothyroidism (see data ). no animal reproductive studies have been conducted. clinical considerations . fetal/ neonatal adverse reactions a fetus exposed to sodium iodide i 131 can develop neonatal hypothyroidism. delay in diagnosis of neonatal hypothyroidism after exposure to sodium iodide i 131 in utero can result in severe sequelae such as decreased mental capacity and delayed bone age. monitor thyroid function in any infant born after in utero exposure to sodium iodide i 131. data human data sodium iodide i 131 crosses the placenta and the fetal thyroid begins to concentrate iodide during the 10-12 th week of gestation. in literature reports of maternal exposures to sodium iodide i 131 at doses of 333 – 8325 mbq (9 – 225 mci) during 4-26 weeks gestational age, the most common adverse outcomes were hypothyroid infants and children. risk summary sodium iodide i-131 solution is contraindicated during lactation because i-131 concentrates in the breast during lactation via the increased expression of the sodium iodide symporter in breast tissue and can lead to hypothyroidism in the infant through breastfeeding. if sodium iodide i-131 is administered postpartum, breastfeeding should not be restarted for the remainder of the postpartum period. in addition, to minimize the absorbed radiation dose to the breast tissue, breastfeeding and breast-pumping should be discontinued for at least 6 weeks before administration of sodium iodide i-131 [see warnings and precautions (5.5)] . infants exposed to sodium iodide i-131 through breast milk are at risk for development of hypothyroidism because sodium iodide i-131 is distributed into breast milk and may reach concentrations equal to or greater than concentrations in maternal plasma(see data ). data published literature describes sodium iodide i-131 transfer into breast milk and uptake by the thyroid of the breastfed infant. the amount of sodium iodide i-131 detected in the breast milk at 36 to 48 hours after administration is 1% to 27% of the injected dose (with injected doses between 1.1 mbq to 5,143 mbq). sodium iodide i-131 is contraindicated in pregnancy because of the risk of fetal hypothyroidism [see warnings and precautions (5.4) and [see use in specific populations (8.1)] . pregnancy testing obtain a pregnancy test in females of reproductive potential and verify the absence of pregnancy before initiating treatment [see dosage and administration (2.2) ]. contraception advise females and males of reproductive potential to use effective contraception during treatment with sodium iodide i-131 solution and for at least six months after the last dose of sodium iodide i-131 solution. infertility females fertility may be impaired with sodium iodide i-131 solution treatment. transient amenorrhea and ovarian insufficiency have been observed after sodium iodide i-131 therapy in females. the literature describes reports of transient menstrual cycle irregularities, including amenorrhea, and ovarian failure in females treated with cumulative doses of 1,000 mbq to 59,000 mbq (27 mci to 1,595 mci) sodium iodide i-131. in a published literature analysis, the effects on fertility occurred in up to 30% of women treated with sodium iodide i-131, and may resolve 12 months after treatment. males fertility may be impaired with sodium iodide i-131 solution treatment. discuss sperm banking for males who are expected to receive a high cumulative dose of sodium iodide i-131. transient dose-related impairment of testicular function after sodium iodide i-131 therapy has been reported in the published literature. the literature describes reports of males treated with sodium iodide i-131 at doses of 370 mbq to 22,000 mbq (10 mci to 595 mci) resulting in transiently impaired testicular function (including spermatogenesis). the risk of persistent testicular dysfunction increases after administration of repeated or high cumulative radioiodide exposure. the safety and effectiveness of sodium iodide i-131 solution have not been established in pediatric patients. pediatric patients are at an increased lifetime risk for malignancy from radiation exposure. clinical experience has not identified differences in safety or effectiveness in geriatric patients compared to younger patients. however, elderly patients are more likely to have decreased renal function and radiation exposure is greater in patients with impaired renal function [see use in specific populations (8.6), clinical pharmacology (12.3) ]. sodium iodide i 131 is primarily excreted by the kidneys. renal function impairment decreases excretion of sodium iodide i 131 and increases the radiation exposure and risk of radiation toxicity. for patients with a history of renal impairment, evaluate renal function for therapeutic planning and consider dosimetry. sodium iodide i 131 is dialyzable. hemodialysis can be used to reduce total body radiation exposure [see clinical pharmacology (12.3)].

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

a a h pharmaceuticals ltd - ascorbic acid - oral tablet - 50mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

kent pharma (uk) ltd - ascorbic acid - oral tablet - 50mg